158602-32-5

Basic information

• Product Name: ETHYL 2-(1-BENZHYDRYLAZETIDIN-3-YLIDENE) ACETATE
• Synonyms: ETHYL 2-(1-BENZHYDRYLAZETIDIN-3-YLIDENE) ACETATE;Acetic acid, 2-[1-(diphenylMethyl)-3-azetidinylidene]-, ethyl ester
• CAS NO: 158602-32-5
• Molecular Formula: C20H21NO2
• Molecular Weight: 307.4
• Mol File: 158602-32-5.mol

Chemical Properties

• Boiling Point: 415.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.191±0.06 g/cm3(Predicted)
• PKA: 5.60±0.20(Predicted)
• CAS DataBase Reference: ETHYL 2-(1-BENZHYDRYLAZETIDIN-3-YLIDENE) ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(1-BENZHYDRYLAZETIDIN-3-YLIDENE) ACETATE(158602-32-5)
• EPA Substance Registry System: ETHYL 2-(1-BENZHYDRYLAZETIDIN-3-YLIDENE) ACETATE(158602-32-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 158602-32-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
ETHYL 2-(1-BENZHYDRYLAZETIDIN-3-YLIDENE) ACETATE is used as a reagent in organic synthesis for its unique structural properties that facilitate the creation of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, ETHYL 2-(1-BENZHYDRYLAZETIDIN-3-YLIDENE) ACETATE is used as a precursor in the development of new drugs, leveraging its distinctive chemical structure to contribute to the synthesis of novel medicinal compounds.
Used in Research and Development:
ETHYL 2-(1-BENZHYDRYLAZETIDIN-3-YLIDENE) ACETATE is utilized in research and development settings to explore its properties and potential applications, with ongoing studies aiming to uncover its full potential in various chemical and pharmaceutical processes.

Upstream product

• 40320-60-3 N-benzhydryl 3-azetidinone 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 

Downstream Products

• 942307-65-5 1-Benzhydryl-3-(2-methoxyethyl)azetidine 
• 712317-32-3 ethyl 2-(3-azetidinyl)acetate hydrochloride 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-b]indole Derivatives against Gram-Negative Multidrug-Resistant Pathogens

Due to the poor permeability across Gram-negative bacterial membranes and the troublesome bacterial efflux mechanism, only a few GyrB/ParE inhibitors with potent activity against Gram-negative pathogens have been reported. Among them, pyrimido[4,5-b]indol

NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF

It is intended to provide a novel compound having high antitumor activity and low toxicity to normal cells. The present invention provides a pyridone carboxylic acid derivative represented by the following formula (1) or a salt thereof wherein R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; R3 to R6 each represent a hydrogen atom or the like; R7 represents a hydrogen atom or the like; R8 represents a hydrogen atom, a halogen atom, the following formula (a) (wherein Ra1 and Ra2 each represent a hydrogen atom, a hydroxy group, an optionally substituted lower alkyl group or the like) or the like, or R7 and R8 together represent —N—OR10 (wherein R10 represents a hydrogen atom, an optionally substituted lower alkyl group, or an aralkyl group), or R7 and R8 form an optionally substituted 4- to 6-membered saturated hetero ring together with the adjacent carbon atom, or the like; R9 represents a hydrogen atom or the like; X represents a nitrogen atom or the like; and Y represents a nitrogen atom or the like.

Preparation method of tert-butyl-5-(hydroxymethyl)-7-oxa-2-azaspiro[3.5]nonane-2-formate

The invention relates to a preparation method of tert-butyl-5-(hydroxymethyl)-7-oxa-2-azaspiro[3.5]nonane-2-formate, and mainly solves the technical problem that no proper industrial synthesis methodexists at present. The product is synthesized by six steps, and the preparation method comprises the steps: a first step, a compound 1 is subjected to Swern oxidation reaction to generate a compound 2; a second step, a compound 3 is obtained through a Horner-Wadsworth-Emmons reaction; a third step, a compound 4 is obtained through Michael addition; a fourth step, a compound 5 is obtained through reduction of the compound 4 with lithium tetrahydroaluminum; a fifth step, the compound 5 is dehydrated and retained with a ring to obtain a compound 6 under the action of sodium hydrogen; and a sixthstep, hydrogenation is preformed to remove a protective group, and then a protective group is added to obtain the target compound 7. The obtained compound is a useful intermediate or product for synthesis of many drugs.

Rhodium catalyzed C-C bond cleavage/coupling of 2-(azetidin-3-ylidene)acetates and analogs

The C-C bond cleavage/coupling of 2-(azetidin-3-ylidene)acetates with aryl boronic acids catalyzed by a rhodium complex was studied with a "conjugate addition/β-C cleavage/protonation" strategy.

AZETIDINYL QUINOLONES AS ANTIBACTERIAL AGENTS

Compounds of formula (I) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compoun

QUINAZOLINE-2, 4-DIONES AS ANTIBACTERIAL AGENTS

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of